Cencora (COR) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Core Insights - Cencora reported $79.05 billion in revenue for Q3 2024, a year-over-year increase of 14.7% and a surprise of +1.76% over the Zacks Consensus Estimate of $77.68 billion [1] - The EPS for the quarter was $3.34, compared to $2.86 a year ago, with a surprise of +4.05% over the consensus estimate of $3.21 [1] Revenue Breakdown - Total U.S. Healthcare Solutions revenue was $71.67 billion, exceeding the average estimate of $70.29 billion, reflecting a year-over-year change of +15.7% [3] - Total International Healthcare Solutions revenue was $7.38 billion, slightly below the average estimate of $7.40 billion, with a year-over-year change of +5.5% [3] - Intersegment eliminations reported at -$3.08 million, worse than the estimated -$1.87 million, showing a significant year-over-year change of +129.4% [3] Stock Performance - Cencora's shares have returned +6% over the past month, outperforming the Zacks S&P 500 composite's +0.7% change [4] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [4]